This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Regulatory Updates

PHSS Dec Reg Update: Industry Stakeholder meeting on Brexit report; Dose Escalation; USA / EU MRA u

03 December 2018  
Posted by: Tamsin Marshall
Share |

PHSS Regulatory Update Dec 2018

 

During the last 4 weeks there have been several developments in the regulation of the pharmaceutical industry. This month reported issues have come from the Australian, EU, US and PIC/s regulatory authorities.

Once again, we report on a USA compounding pharmacy making and releasing products where there is a lack of sterility assurance. The company also is said to have ignored FDA advice on more than one occasion.

The topics covered in this edition of the “Update” include:

 

Europe

  • Report of Industry Stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products

  • Ph. Eur. seeks feedback on general chapter covering depyrogenation in parenteral preparations

  • Dose Escalation – is it GCP compliant?

  • Relevant training for GCP laboratory staff

USA 

 

  • USA / EU MRA update

  • FDA Proposes Critical First Steps to Harmonize the Global Scientific and Technical Standards for Generic Drugs

  • Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products

  • FDA alerts health care professionals and patients not to use sterile drug products from Pharm D Solutions

  • Measles vaccine-Option to lower lot release specification for required measles antibody potency testing


International

 

Australia

 

  •  Inclusion of Active Pharmaceutical Ingredient in Australia-Canada Mutual Recognition Agreement.

 

PIC/s

  • Revised draft PIC/s guidance on good practices for data management and integrity in regulated GMP/GDP environments

Membership Software Powered by YourMembership  ::  Legal